Interventional Cardiology and Department of Cardiology, Clinica Mediterranea, Naples, Italy.
Interventional Cardiology, IRCCS Multimedica, Milan, Italy.
Int J Cardiol. 2011 Jun 2;149(2):199-204. doi: 10.1016/j.ijcard.2010.01.009. Epub 2010 Feb 6.
In an attempt to improve the stent's safety, development of bare metal stents (BMS) continues, with new materials and geometry. Chrono (CID, Italy) is a thin strut cobalt-chromium (Co-Cr) stent combining the clinical benefits of the bio- and haemo-compatible Carbofilm coating.
We assessed the safety and efficacy of percutaneous coronary interventions (PCI) using the new Co-Cr Chrono stent in patients undergoing elective PCI for de novo lesions in native coronary vessels. The patients were followed for 12 months for the occurrence of major cardiac events (MACE, defined as death, myocardial infarction, repeat PCI and bypass surgery). Patients with complex (B2/C) lesions were compared to those with non-complex lesions (A/B1).
A total of 340 consecutive patients were analysed: 155 patients with complex lesions (Complex group) and 185 patients with non-complex lesions (Non-complex group). Dual antiplatelet therapy was maintained >1 month in 21% of patients in both Complex and Non-complex group. Stent length was longer in the Complex group (25 ± 10 mm versus 17 ± 6 mm; p<0.001). Stent diameter <3.0 mm was most frequent in the Complex group (35.5% versus 27.5%; p<0.05). During the 12-month follow-up period MACE occurred in 10.6% of the global population (12.3% in the Complex group and 9.2% in the Non-complex group; p=0.43). Repeat PCI was most frequent in the Complex group (9.7% versus 3.8%; p=0.044). The incidence of definite and probable stent thrombosis (ARC criteria) was 1.29% in the Complex group and 1.08% in the Non-complex group (p=1.0).
Implantation of the Co-Cr Chrono stent results in a good safety and efficacy for both complex and non-complex de-novo coronary artery lesions.
为了提高支架的安全性,继续开发了裸金属支架(BMS),采用了新材料和几何形状。Chrono(CID,意大利)是一种薄壁钴铬(Co-Cr)支架,结合了生物和血液相容性 Carbofilm 涂层的临床益处。
我们评估了新的 Co-Cr Chrono 支架在接受择期经皮冠状动脉介入治疗(PCI)的患者中用于治疗原发性冠状动脉病变的安全性和疗效。患者在 12 个月内随访主要心脏不良事件(MACE,定义为死亡、心肌梗死、再次 PCI 和旁路手术)的发生情况。比较了复杂病变(B2/C)患者和非复杂病变(A/B1)患者。
共分析了 340 例连续患者:155 例复杂病变患者(复杂组)和 185 例非复杂病变患者(非复杂组)。在复杂组和非复杂组中,有 21%的患者持续使用双联抗血小板治疗>1 个月。复杂组的支架长度较长(25 ± 10 mm 比 17 ± 6 mm;p<0.001)。复杂组中支架直径<3.0 mm 最常见(35.5%比 27.5%;p<0.05)。在 12 个月的随访期间,总人群中发生 MACE 的比例为 10.6%(复杂组为 12.3%,非复杂组为 9.2%;p=0.43)。重复 PCI 最常见于复杂组(9.7%比 3.8%;p=0.044)。复杂组和非复杂组的明确和可能的支架血栓形成(ARC 标准)发生率分别为 1.29%和 1.08%(p=1.0)。
植入 Co-Cr Chrono 支架治疗复杂和非复杂原发性冠状动脉病变的安全性和疗效良好。